SpyGlass Pharma reports 4-year glaucoma implant trial data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LVS
6. SAP
7. CSX
8. LRCX
9. SPY
10. MRK

Go back to SpyGlass Pharma reports 4-year glaucoma implant trial data

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

October 19, 2026 8:00 AM EDT

Groundbreaking 4-year safety and efficacy results:

37% reduction in mean intraocular pressure (IOP) across all dose groups86% of patients remained off all topical IOP-lowering drops90% of patients maintained 20/25 best corrected distance visual acuity (BCDVA)No product-related adverse events were reported


IRVINE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through... More